Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asunaprevir/beclabuvir/daclatasvir - Bristol-Myers Squibb

Next Previous
X
Search
Drug Profile

Asunaprevir/beclabuvir/daclatasvir - Bristol-Myers Squibb

Alternative Names: Asunaprevir/daclatasvir/BMS 791325; BMS 791325/asunaprevir/daclatasvir; Daclatasvir/BMS 791325/asunaprevir; DCV 3DAA FDC; DCV-TRIO; DCV/ASV/BMS-791325; Ximency

Latest Information Update: 30 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Azabicyclo compounds; Benzazepines; Biphenyl compounds; Carbamates; Cyclohexanes; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Imidazoles; Indoles; Isoquinolines; Organic bridged compounds; Phenyl ethers; Piperazines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 01 Mar 2017 Toranomon Hospital initiates enrolment in a clinical trial for Hepatitis-C in Japan (UMIN000026909)
  • 20 Feb 2017 Bristol-Myers Squibb initiates enrolment in an observational, postmarketing commitment study for Hepatitis C in Japan (NCT03071133)
  • 01 Feb 2017 Launched for Hepatitis C in Japan (PO) before February 2017

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top